Covid-19 Impact on Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market, Global Research Reports 2020-2021
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.
This report provides a complete quantitative data and qualitative analysis on the global market for Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics, including the following market information:
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Oral Therapy
Injectable Therapy
Based on the Application:
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.
This report provides a complete quantitative data and qualitative analysis on the global market for Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics, including the following market information:
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Oral Therapy
Injectable Therapy
Based on the Application:
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
